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Table 1. Angiographic, IVUS and Clinical Results
DESyne Endeavor p-value
Angiographic Results
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMPES 29.5% (p¼0.55, ﬁg 1a). The event rate between 2 and 5 years was lower in
Genous 4.1% vs PES 17.2%(p¼0.011, ﬁg 1b). The composite of death and MI was
6.3% in Genous vs 12.0% in PES (p¼0.19). Deﬁnite stent thrombosis was observed in
4 cases in PES versus non in Genous.Baseline RVD (post-procedure) 2.840.43 2.910.38 0.2
9-month angiographic/IVUS
In-stent Late Lumen Loss 0.110.32 0.630.42 < 0.001
% neointimal volume 4.55.1 20.911.3 <0.001
Clinical Results
12-month DoCE (%) 4.3 7 0.51
Clinically-indicated TLR 1.4 5.6 0.18
24-month DoCE (%) 4.3 9 0.14
Clinically-indicated TLR 1.4 7 0.04
36-month DoCE (%) 5 12.7 0.057
Clinically-indicated TLR 1.4 9.9 0.008
48-month DoCE (%) 6.5 12.7 0.19
Clinically-indicated TLR 2.2 8.5 0.06Conclusions: The ﬁrst randomized and adjudicated long-term results of the Genous
versus a PES at 5 years show comparable performance and safety. Between two and
ﬁve years a signiﬁcant higher event rate was observed in the PES group compared
with the Genous group. Importantly, no deﬁnite stent thrombosis was observed in the
Genous treated group, compared with four cases in the PES group.
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Background: Evaluate the long-term safety and effectiveness of the Elixir DESyne
Novolimus-Eluting Coronary Stent System (CSS) compared to the Endeavor Zotar-
olimus-Eluting CSS (Medtronic, Santa Rosa, CA) through assessment of clinical,
angiographic, and IVUS endpoints through 5 years.
Methods: 210 patients were randomized 2:1 either to the DESyne CSS loaded with
5 mcg/mm of stent length of Novolimus, a sirolimus metabolite, eluted via a durable
methacrylate polymer, or to the Endeavor CSS loaded with 10 mcg/mm of stent
length of Zotarolimus eluted via a durable phosphoryl choline polymer. All patients
were analyzed for the primary endpoint of late lumen loss (LLL) assessed by QCA
at 9 months. All patients also underwent evaluation for secondary endpoints, which
included a device-orientated composite endpoint (DoCE) deﬁned as: cardiac death;
target vessel MI; clinically-indicated target lesion revascularization (TLR); clini-
cally-indicated target vessel revascularization (TVR); and stent thrombosis all
evaluated at 1, 6, 9, and 12 months and annually through 5 years. In-stent and in-
segment LLL were assessed at 9 months. A subset of patients underwent IVUS
evaluation 9 months.
Results: The study met the non-inferiority endpoint and also demonstrated superiority
of the DESyne CSS as compared to control. Table 1 summarizes angiographic, IVUS,
and clinical results through 4 years.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/SteConclusions: The DESyne CSS met the non-inferiority endpoint and also demon-
strated superiority as compared to Endeavor at 9 months. Clinical results through 4
years demonstrated lower DoCE (6.5 and 12.7, p¼0.19) and signiﬁcantly lower
clinically-indicated TLR (2.2 and 8.5 p¼0.06) for DESyne vs Endeavor. Final clinical
results through 5 years will be presented.
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Background: US guidelines recommend 12 months of uninterrupted DAPT after
implantation of DES. Prolonged and more powerful DAPT regimens have offered
beneﬁt by reducing VLST, but at the cost of increased risk of bleeding. There is an
emerging need for new stents that are less dependent on prolonged DAPT. The
BioFreedom stent (BFD) releases Biolimus A9, without using a polymer or
binder. Based on an animal model, 98% of the drug diffuses to the vessel wall
within 1 month, leaving a BMS in place. This is generating the hypothesis that BFD
can be associated with a need for shorter DAPT and safety advantage compared
to a polymer based DES. This First-In-Man trial aims to demonstrate the safety
and effectiveness of the BFD compared to the Taxus Liberté pactilaxel-eluting
stent (PES).
Methods: BioFreedom FIM is a prospective, multi-center, randomized trial. 182
patients were enrolled and randomized to BFD Standard Dose (SD, 15.6 mg/mm), or
BFD Low Dose (LD, 7.8 mg/mm), or Taxus Liberté DES. The primary endpoint was
in-stent Late Loss (LL) at 12 months. The main secondary endpoints are IVUS
neointimal volume at 4 & 12 months; MACE (death, MI, emergent bypass or clini-
cally-driven TLR) and ST rates (ARC deﬁned) at 30 days, 4 and 12 months, and then
yearly up to 5 years.
Results: The in-stent LL was non inferior in BFD SD (p non-inf ¼ 0.001) and
trended towards superiority with medians of 0.17mm [0.09, 0.39] vs. 0.35mm
[0.22, 0.57] compared to PES (p sup¼0.11) at 12 months. At 4 years, the clinical
FU was 93.5%. The BFD SD and PES showed similar rates of MACE (BFD SD
13.6% vs. PES 13.3%, p¼1.02) with no deﬁnite/probable ST in any groups.
Interestingly, at 2 years, there was a signiﬁcant difference in adherence to DAPT
between the groups (BFD SD 5.2% vs. PES 18.6%, p¼0.025) which disappeared at
further follow-ups.
Conclusions: The safety and efﬁcacy of the polymer free BioFreedom has been
shown out to 4 years. A large randomized clinical trial (LEADERS FREE) is
currently studying the possibility of using this stent in patients with high
bleeding risk, unable to tolerate a prolonged course of DAPT. The 5-year ﬁnal
results of BioFreedom FIM will be reported for the 1st time during this
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